Rocket Pharma Reports Patient Death In Rare Disease Gene Therapy Trial, FDA Puts Clinical HoldBenzinga • 05/27/25
Rocket Pharmaceuticals shares plunge after FDA halts key gene therapy trial following patient deathProactive Investors • 05/27/25
Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon DiseaseBusiness Wire • 05/27/25
Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell TherapyBusiness Wire • 05/15/25
Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell TherapyBusiness Wire • 05/09/25
Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent ProgressBusiness Wire • 05/08/25
Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare ConferenceBusiness Wire • 04/03/25
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in FocusZacks Investment Research • 02/28/25
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent ProgressBusiness Wire • 02/27/25
Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 01/15/25
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/02/25
Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common StockBusiness Wire • 12/11/24
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx ConferenceBusiness Wire • 11/26/24
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: AnalystBenzinga • 11/19/24
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association ConferenceBusiness Wire • 11/18/24
Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science SessionsBusiness Wire • 11/12/24
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare ConferenceBusiness Wire • 11/08/24
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent ProgressBusiness Wire • 11/07/24